awards grant
- A Multicenter, Randomized, Double-Blind Placebo Controlled Study to Evaluate the Safety and Efficacy of School 530348 in a
- A Phase 3, Safety & Efficacy Study of Boceprevir in Previousuntreated Subjects With Chronic Hepatitis C Genotype 1
- A Phase III Randomized Clinical Trial of Pembrolizumab (Mk-3475) Versus Paclitaxel, Docetaxel or Vinflunine....
- A Phase III, 12 Week, Dbld, Placebo-Ctrl Efficacy & Safety Study of Preladenant in Subjects With Moderate to Severe...
- Assessment of Optimal Regulated Interferon Therpy
- Boceprevir/Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects.....P06086
- Comparison of Peg-Intron 1.5Ug/Kg/Wk Plus Rebetol Vs Peg-Intron 1Ug/Kg/Wk Plus Rebetol Vs Pegasys 180Ug/Wk .....
- Long-Term Follow-Up Protocol to Assess Patients After Completing 24 Weeks of Follow-Up in a Spri Clinical
- Naturally Occurring Mutations to Hepatitis C Virus Protease Inhibitors Analyzed By Deep Sequencing
- Open Label Limited Access Protocol of Posaconazole in Invasive Fungal Infection
- Open-Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections
- P2095-327 - Openlabel, Limited Access Protocol of Posaconazole in Invasive Fungal Infections
- Po1899-38 a Randomized Controlled Trial of Posaconazole (Sch 56592) V. Standard Azole Therapy for the Prevention Of
- Safety and Pharmacokinetics of Single Dose Intravenous Anti-Il 23 Antibody School 900222 in Subjects With Crohns Disease
- Study of the Safety Tolerance and Efficacy of Sch-5692 vs Flu-Conazole in the Prophylaxis of Invasive Fungai Infections...
- The Effect of Acadesine on Clinically Significant Adverse Cardiovascular and Cerebrovascular Events in High-Risk .......
- Vicriviroc (Sch 417690) in Combination Treatment with Optimized Art Regimen (Victor-1)